APHP, Avicenne Hospital, Geriatric Department, Coordination Unit in Geriatric Oncology, F-93000, Bobigny, France; Université Paris 13, Sorbonne Paris Cité, Health Education and Practices Laboratory (LEPS EA3412), F-93017, Bobigny, France.
APHP, Avicenne Hospital, Department of Medical Oncology, F-93000, Bobigny, France.
Clin Nutr. 2018 Aug;37(4):1101-1113. doi: 10.1016/j.clnu.2017.07.010. Epub 2017 Jul 13.
BACKGROUND & AIMS: To assess the prevalence of sarcopenia before cancer treatment and its predictive value during the treatment.
We searched MEDLINE via PubMed for articles published from 2008 to 2016 that reported prospective observational or interventional studies of the prevalence of pre-therapeutic sarcopenia and its consequences in adults with cancer who were 18 years or older. Two independent reviewers selected articles based on titles and/or abstracts before a complete review. Sarcopenia had to be measured before cancer treatment. Methods recommended by consensuses (CT scan, MRI, dual X-ray absorptiometry or bio-impedancemetry) to assess sarcopenia were considered. Characteristics of the studies included the prevalence of pre-therapeutic sarcopenia and the prognostic value for outcomes during the cancer treatment.
We selected 35 articles involving 6894 participants (in/out patients, clinical trials). The mean age ranged from 53 to 69.6 years. Pre-therapeutic sarcopenia was found in 38.6% of patients [95% CI 37.4-39.8]. Oesophageal and small-cell lung cancers showed the highest prevalence of pre-therapeutic sarcopenia. Pre-therapeutic sarcopenia was significantly and independently associated with post-operative complications, chemotherapy-induced toxicity and poor survival in cancer patients.
Pre-therapeutic sarcopenia is highly prevalent in cancer patients and has severe consequences for outcomes of cancer patients.
评估癌症治疗前肌少症的流行情况及其在治疗期间的预测价值。
我们通过 PubMed 中的 MEDLINE 检索了 2008 年至 2016 年期间发表的前瞻性观察性或干预性研究，报告了 18 岁及以上癌症成人患者治疗前肌少症的流行情况及其对癌症治疗结果的影响。两名独立的审查员在进行完整审查之前，根据标题和/或摘要选择了文章。肌少症必须在癌症治疗前进行测量。评估肌少症的共识推荐方法（CT 扫描、MRI、双能 X 线吸收测定法或生物电阻抗法）被认为是合适的。研究特征包括治疗前肌少症的流行情况以及癌症治疗期间结果的预后价值。
我们选择了 35 篇涉及 6894 名参与者（门诊/住院患者、临床试验）的文章。平均年龄范围为 53 至 69.6 岁。治疗前肌少症在 38.6%的患者中发现[95%CI 37.4-39.8]。食管癌和小细胞肺癌的治疗前肌少症患病率最高。治疗前肌少症与癌症患者术后并发症、化疗诱导的毒性和不良生存显著且独立相关。
癌症患者治疗前肌少症的患病率较高，对癌症患者的结局有严重影响。
